Summary of half maximal inhibitory concentration (IC50) values for Aurora kinase inhibitors against pediatric and infant leukemia cell lines, normal lymphocytes and bone marrow stroma.

Tumour cells from six B-ALL cell lines (C1, SEM, B1, UOCB1, Nalm6, KOPN8), two T-ALL cell lines (CEM, Molt-3), three AML cell lines (Molm13, MV4-11, TIB-202) and three APML cell lines (NB4, HL-60, HL-60 RA), as well as normal lymphocytes and bone marrow stroma, were treated with individual inhibitors at eight concentrations (1×10−6 to 10 µM). After four days in culture, cell viability was quantified by Alamar blue assay or automated microscopy and percent growth inhibition was determined by comparison to cells treated with DMSO control. The calculated IC50 values ± standard deviations are representative of three separate experiments.